PRAC has issued this precaution, to ensure that daclizumab continues to be used as safely as possible while a review of its liver safety is ongoing. This review was started after the death from liver injury (fulminant liver failure) of a patient involved in an ongoing observational study, as well as four cases of serious liver injury.